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Evaluation of Oxacillin and Cefoxitin Disk and MIC Breakpoints for
Prediction of Methicillin Resistance in Human and Veterinary Isolates
of Staphylococcus intermedius Group
S. D. Lawhon,f M. A. Wallace,c T. Stanley,g E. Burd,g,h J. Hindler,a

UCLA David Geffen School of Medicine, Los Angeles, California, USAa; Landstuhl Regional Medical Center, Landstuhl, Germanyb; Washington University School of
Medicine, St. Louis, Missouri, USAc; Weill Cornell Medical College, New York, New York, USAd; Children’s Hospital of Los Angeles, Los Angeles, California, USAe; Veterinary
Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, USAf; Emory University School of Medicine, Atlanta, Georgia, USAg; Emory Antibiotic
Resistance Center, Atlanta, Georgia, USAh

Staphylococcus pseudintermedius is a coagulase-positive species that colonizes the nares and anal mucosa of healthy dogs and
cats. Human infections with S. pseudintermedius range in severity from bite wounds and rhinosinusitis to endocarditis; historically, these infections were thought to be uncommon, but new laboratory methods suggest that their true incidence is underreported. Oxacillin and cefoxitin disk and MIC tests were evaluated for the detection of mecA- or mecC-mediated methicillin resistance in 115 human and animal isolates of the Staphylococcus intermedius group (SIG), including 111 Staphylococcus
pseudintermediusand 4 Staphylococcus delphini isolates, 37 of which were mecA positive. The disk and MIC breakpoints evaluated included the Clinical and Laboratory Standards Institute (CLSI) M100-S25 Staphylococcus aureus/Staphylococcus lugdunensis oxacillin MIC breakpoints and cefoxitin disk and MIC breakpoints, the CLSI M100-S25 coagulase-negative Staphylococcus (CoNS) oxacillin MIC breakpoint and cefoxitin disk breakpoint, the CLSI VET01-S2 S. pseudintermedius oxacillin MIC
and disk breakpoints, and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) S. pseudintermedius cefoxitin disk breakpoint. The oxacillin results interpreted by the VET01-S2 (disk and MIC) and M100-S25 CoNS (MIC) breakpoints agreed with the results of mecA/mecC PCR for all isolates, with the exception of one false-resistant result (1.3% of mecA/
mecC PCR-negative isolates). In contrast, cefoxitin tests performed poorly, ranging from 3 to 89% false susceptibility (very
major errors) and 0 to 48% false resistance (major errors). BD Phoenix, bioMérieux Vitek 2, and Beckman Coulter MicroScan
commercial automated susceptibility test panel oxacillin MIC results were also evaluated and demonstrated >95% categorical
agreement with mecA/mecC PCR results if interpreted by using the M100-S25 CoNS breakpoint. The Alere penicillin-binding
protein 2a test accurately detected all mecA-positive isolates, although for four isolates, cefoxitin induction was required prior to
testing. These data demonstrate that the cefoxitin surrogate test does not reliably detect the presence of mecA in S. pseudintermedius isolates and that laboratories should perform oxacillin disk or MIC tests of these isolates when they are encountered.

S

taphylococcus pseudintermedius is a coagulase-positive, hemolytic species that colonizes the nares and anal mucosa of
healthy dogs and cats (1–4). Clinically, S. pseudintermedius is the
most common cause of canine pyoderma and occasionally causes
urinary tract and joint infections in dogs and cats (5–8). Phenotypically, S. pseudintermedius is difficult to differentiate from
Staphylococcus intermedius and Staphylococcus delphini, which are
also coagulase-positive veterinary staphylococci. Collectively,
these three species are referred to as the S. intermedius group
(SIG). Differentiation of the members of this group requires molecular analysis (9), although matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has
also shown promise for reliable differentiation of the members of
the SIG (4, 10–13).
Human infections caused by S. pseudintermedius are reported
sporadically and range in severity from bite wounds and rhinosinusitis to endocarditis, (14–17). However, infections caused by S.
pseudintermedius in humans are likely underreported (18), as clinical laboratories may inaccurately report these isolates as Staphylococcus aureus on the basis of positive coagulase or staphylococcal
latex agglutination reactions (19). Recognition of phenotypic
traits atypical of S. aureus, such as off-white colony color and the
presence of double-zone beta-hemolysis on sheep blood agar

March 2016 Volume 54 Number 3

(SBA) with appropriate follow-up testing, is required for accurate
identification. The introduction of MALDI-TOF MS systems in
many clinical laboratories for identification of bacteria may result
in increased reporting of S. pseudintermedius, as has been noted by
our laboratories (R.M.H. and C.-A.D.B., personal observations).
Unlike human isolates of S. aureus, veterinary isolates of SIG
are typically susceptible to methicillin (20). However, the incidence of methicillin-resistant S. pseudintermedius (MRSP) in dogs
has increased, presenting a major treatment challenge for veterinarians (21). In face of this emerging resistance, the Clinical and
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TABLE 1 Breakpoints evaluated for prediction of S. pseudintermedius methicillin resistance
Oxacillin breakpoint
Disk (mm)
a

Cefoxitin breakpoint
MIC (g/ml)

b

Disk (mm)

MIC (g/ml)

S

R

S

R

S

R

S

R

CLSI M100-S25 S. aureus/S.
lugdunensis
CLSI M100-S25 CoNS
CLSI VET01-S2 S.
pseudintermedius
EUCAST S.
pseudintermedius

NAc

NA

ⱕ2

ⱖ4

ⱖ22

ⱕ21

ⱕ4

ⱖ8

NA
ⱖ18

NA
ⱕ17

ⱕ0.25
ⱕ0.25

ⱖ0.5
ⱖ0.5

ⱖ25
NA

ⱕ24
NA

NA
NA

NA
NA

NA

NA

NA

NA

ⱖ35

⬍35

NA

NA

a

S, susceptible.
R, resistant.
c
NA, not applicable.
b

Laboratory Standards Institute (CLSI) veterinary group revised
recommendations for the detection of methicillin resistance in
these isolates (22–24) and now stipulates that oxacillin disk or
MIC testing be performed and interpreted by using S. pseudintermedius-specific breakpoints (Table 1). These guidelines are found
in the CLSI VET01-S2 document (25).
With the close contact between humans and companion animals, zoonotic transfer of MRSP to humans is inevitable. Few, if
any, clinical laboratories in the United States routinely access the
CLSI VET01-S2 document and rely on the CLSI M100-S25 standard for instructions on how to perform susceptibility tests and
interpret their results for human isolates. This fact, coupled with
frequent misidentification of S. pseudintermedius as S. aureus, has
resulted in variable S. pseudintermedius isolate antimicrobial susceptibility testing and interpretation practices across clinical laboratories. Moreover, no automated susceptibility test system is
cleared by the U.S. Food and Drug Administration (FDA) for the
testing of human isolates of S. pseudintermedius, and the ability of
these systems to accurately detect MRSP is unknown.
The objective of this study was to evaluate cefoxitin and oxacillin disk zones and MICs, compared to mecA and mecC PCR, for
a collection of 115 human and veterinary SIG isolates. Disk zones
and MICs were interpreted by using the VET01-S2 oxacillin
breakpoints, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) cefoxitin breakpoints for S. pseudintermedius (26), and the existing S. aureus and coagulase-negative
Staphylococcus (CoNS) oxacillin and cefoxitin breakpoints in
M100-S25. The results of these data were presented to the CLSI
Antimicrobial Susceptibility Testing Subcommittee in July 2015,
which led to the addition of S. pseudintermedius-specific interpretative criteria for oxacillin disk and MIC data to the forthcoming
M100-S26 document. In addition, three commercial automated
susceptibility test systems used in human clinical laboratories
were evaluated, along with a penicillin-binding protein 2a
(PBP2a) test, for the detection of MRSP.
MATERIALS AND METHODS
Bacterial isolates. A total of 115 isolates were included in this study.
Human isolates (n ⫽ 45) were collected from the following geographically
distinct academic medical centers: the Ronald Reagan UCLA Medical
Center, Los Angeles, CA (n ⫽ 12); the Emory University School of Medicine, Atlanta, GA (n ⫽ 4); Washington University, St. Louis, MO (n ⫽
12); the Centers for Disease Control and Prevention, Atlanta, GA (n ⫽ 7);
the University of Iowa Hospital and Clinics, Iowa City, IA (n ⫽ 2); and the
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R. M. Alden Research Laboratory, Culver City, CA (n ⫽ 8). Veterinary
isolates (n ⫽ 70) were obtained from the Texas A&M School of Veterinary
Medicine. Identification of isolates was performed according to the standard operating procedures of the submitting institution and confirmed at
a central laboratory by a nucleic acid-based assay (9).
Antimicrobial susceptibility testing. Isolates were stored at ⫺70°C in
brucella broth plus 15% glycerol (BD, Sparks, MD) and subcultured twice
on SBA prior to testing. Well-isolated colonies were used to prepare a
suspension equivalent to a 0.5 McFarland standard. This suspension was
then used to inoculate Mueller-Hinton agar (BD) for disk diffusion (DD),
broth microdilution (BMD) panels and automated susceptibility cards/
panels according to the CLSI (DD and BMD) or the manufacturer’s instructions. BMD was performed in cation-adjusted Mueller-Hinton
broth (Difco, BD) on panels prepared at UCLA according to CLSI standards (27). Oxacillin was tested at 2-fold dilutions spanning a concentration range of 0.25 to 16 g/ml, whereas cefoxitin was tested at a single
concentration of 4 g/ml in duplicate. For DD tests, disks containing 1 g
oxacillin or 30 g cefoxitin (BBL, BD) were used. Both BMD and DD tests
were incubated at 35°C in ambient air for 24 h, and results were examined
visually by two independent readers.
Automated antimicrobial susceptibility testing was performed with
the Phoenix PMIC-8 panel (BD Diagnostics Systems, Franklin Lakes, NJ),
the Vitek 2 AST-GP71 card (bioMérieux, Inc., Durham, NC), and the
MicroScan PM29 panel (Beckman Coulter, Inc., Brea, CA) at the Children’s Hospital of Los Angeles, UCLA, and Children’s Healthcare of Atlanta, respectively, in accordance with the manufacturer’s specifications.
Quality control was done by testing S. aureus ATCC 25923 (DD), S. aureus
ATCC 29213 (BMD), S. aureus ATCC BAA-976, S. aureus ATCC BAA977, and S. aureus ATCC BAA-1026 for the Vitek 2 card; S. aureus ATCC
29213, S. aureus ATCC 43300, and S. aureus BAA-977 for the MicroScan
panel; and S. aureus ATCC 29213 and S. aureus BAA-977 for the Phoenix
panel.
mecA and mecC detection, SCCmec typing, and repetitive-sequence
PCR. Isolates were grown on 5% sheep blood agar (Hardy Diagnostics,
Santa Maria, CA), and DNA was extracted with the BiOstic Bacteremia
DNA isolation kit (Mo Bio Laboratories, Carlsbad, CA). A multiplex PCR
to detect and differentiate mecA and mecC (mecALGA251) was performed
by using a modification of a previously described method (36). A PCR
with primers mecCF (5=-GAAAAAAAGGCTTAGAACGCCTC-3=),
mecCR (5=-GAAGATCTTTTCCGTTTTCAGC-3=), mecAP4 (5=-TCCA
GATTACAACTTCACCAGG-3=), and mecAP7 (5=-CCACTTCATATCT
TGTAACG-3=) was performed with Ready-To-Go PCR beads (GE
Healthcare). PCR products were visualized on a 1.5% agarose gel. Known
mecA- and mecC-positive MRSA strains USA300 and 72796, respectively,
were used as controls.
A multiplex PCR to detect and differentiate SCCmec types I to V was
also performed on all isolates by a method described previously (28). To
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TABLE 2 Summary of study isolates
SCCmec type (no. of
isolates)

Rep-PCR clonal
lineage(s)a

Blood, ethmoid sinus drainage,
wound, ear, skin, abscess
Blood, dog bites, cat bites,
wounds
Wounds
Wounds

3

IV (2), V (1)

A, D, F

0

None detected

F

1
0

V (1)
Not detected

F
A, D, E, F

Unknown
Blood, wound, endotracheal
aspirate
Pyoderma

0
0

Not detected
Not detected

A, F
A, E, F

33

III (9), IV (8), V (9)

A, B, C, D, E, F

No. of
isolates

Source(s)

Specimen source(s)

UCLA (CA)

12

Human

R. M. Alden Research Laboratory
(CA)
Washington University (MO)
Emory University School of Medicine
(GA)
University of Iowa (IA)
CDCa

8

Human

12
4

Human
Human

2
7

Human
Human

Texas A&Ma

70

Canine, feline,
equine,
porcine

a

The state from which the isolate was acquired was unavailable.

analyze the phylogenetic relatedness of the isolates used in this study,
repetitive-sequence PCR (rep-PCR) was performed as previously described (29, 30). The banding patterns obtained on a virtual gel were
compared to determine the similarity index. Isolates with a similarity
index of ⱖ95% were considered to be identical. For analysis, isolates that
clustered together were given similar letter designations (A to F) to indicate similarity.
PBP2a test. The Alere PBP2a Culture Colony Test (Alere Inc., Scarborough, ME) was used to test colonies grown for 24 h according to the
manufacturer’s instructions for S. aureus. All 115 isolates were tested for
noninduced and induced PBP2a expression. Colonies from the same plate
used to prepare inoculums for cefoxitin and oxacillin DD, as well as BMD
susceptibility testing, were used for the noninduced PBP2a test. Bacteria
from the edge of the cefoxitin zone of growth inhibition were harvested
and used for the induced PBP2a tests. Quality control was done with the S.
aureus ATCC 43300 (positive control) and ATCC 25923 (negative control) strains for each new lot of PBP2a tests.
Data analysis. MIC and disk results were interpreted by using the
following breakpoints: (i) CLSI VET01-S2 S. pseudintermedius oxacillin
MIC and disk, (ii) CLSI M100-S25 S. aureus/S. lugdunensis oxacillin MIC,
(iii) CLSI M100-S25 S. aureus/S. lugdunensis cefoxitin MIC and disk, (iv)
CLSI M100-S25 CoNS oxacillin MIC, (v) CLSI M100-S25 CoNS cefoxitin
MIC and disk, and (vi) EUCAST S. pseudintermedius cefoxitin disk (Table
1). Categorical agreement (CA), major errors (MEs), and very MEs
(VMEs) were calculated as described by Clark et al. (31). CA was defined
by using the results of the mecA/mecC PCR. MEs were defined as findings
that isolates were resistant to oxacillin or cefoxitin but negative for mecA
and mecC by PCR. The ME rate was calculated by using the number of SIG
isolates negative for mecA and mecC by PCR as the denominator. VMEs
were defined as findings that isolates were susceptible to oxacillin or cefoxitin but positive for mecA or mecC by PCR. The VME rate was calculated by using the number of SIG isolates positive for mecA and mecC by
PCR as the denominator.
Discrepant-result resolution. Isolates with an ME or VME result
compared to the gold standard (mecA/mecC PCR) were retested by subculturing a new culture from the frozen stock and testing it by both the
method that generated the error and the reference method in parallel.

RESULTS

Molecular studies. One hundred fifteen SIG isolates were included in this study, which were further identified as 111 S. pseudintermedius and 4 S. delphini isolates. Forty-five S. pseudintermedius isolates were from human, 56 were from canine, 7 were from
feline, and 2 were from avian specimens, and 1 was from a porcine
specimen (Table 2). The S. delphini isolates were from avian (n ⫽
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1) and equine (n ⫽ 3) specimens. mecA was detected in 37/115
(32.2%) isolates, all S. pseudintermedius, including 4/45 (8.9%)
human and 33/64 (51.6%) veterinary isolates. mecC was not detected in any isolate in this study.
SCCmec typing was performed for all isolates with a multiplex
PCR assay that detects and differentiates SCCmec types I to V. As
shown in Table 2, types III (n ⫽ 9), IV (n ⫽ 10 isolates), and V
(n ⫽ 8 isolates) were identified and found only in mecA-positive
isolates (i.e., no mecA dropout events were detected). Among
the human isolates, only the traditional community-associated
SCCmec types IV and V were identified (Table 2), whereas the
veterinary isolates included types III, IV, and V, as well as seven
isolates that were not typeable by this SCCmec assay. The isolates clustered into six groups by rep-PCR, including 22 in group A
(10 human, 12 veterinary), 1 in group B (veterinary), 2 in group C
(veterinary), 4 in group D (2 human, 2 veterinary), 2 in group E (1
human, 1 veterinary), and 84 in group F (32 human and 52 veterinary). There was no clear division by rep-PCR of isolates from
human, avian, equine, canine, or feline specimens or by the geographic locations at which the isolates were recovered.
Cefoxitin and oxacillin DD and BMD. A clear division between oxacillin MICs was found between mecA-positive and -negative isolates—MICs were ⱖ0.5 g/ml for all mecA-positive isolates and ⱕ0.25 g/ml for all mecA-negative isolates but one (Fig.
1). Similarly, oxacillin zones of ⱕ17 mm were observed for all
mecA-positive isolates, and all mecA-negative isolates but one had
oxacillin zones of ⱖ18 mm (Fig. 2). The outlier isolate was the
same for both disk and MIC tests, for which the measured oxacillin zone was 13 mm and the MIC was 1 g/ml. These results, along
with the mecA and mecC PCR results, were confirmed in duplicate
for this isolate. In contrast to the oxacillin test results, no clear
division in cefoxitin zones was observed between mecA-positive
and -negative isolates (Fig. 3) and only 4/37 (10.8%) mecA-positive isolates grew at 4 g/ml cefoxitin (data not shown).
Categorical interpretation of the disk and MIC results, compared to mecA PCR assay results, was done by using six breakpoints, and the results are presented in Table 3. With the cefoxitin
CLSI M100-S25 S. aureus/S. lugdunensis breakpoints, 28/37 mecApositive isolates were interpreted as susceptible by disk (i.e., 75.7%
VMEs) and 33/37 were interpreted as susceptible by MIC (89.1%
VMEs, Table 3). Among the mecA-positive isolates for which
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No. of mecA⫹
isolates

Institute (state of isolate origin)

Wu et al.

VMEs were observed, cefoxitin zones ranged from 22 to 38 mm
(Fig. 3) and MICs were ⱕ4 g/ml. All mecA-negative isolates were
susceptible to cefoxitin by both disk and MIC tests, yielding 0%
MEs (Table 3). When the data were interpreted by the CLSI M100-

S25 S. aureus/S. lugdunensis oxacillin MIC breakpoint, 8/37 mecApositive isolates were susceptible to oxacillin by MIC (21.6%
VMEs). All eight VMEs were obtained with isolates with measured
oxacillin MICs of 1 to 2 g/ml, just below or at the susceptibility

FIG 2 Distribution of oxacillin growth inhibition zone diameters for 115 isolates of S. pseudintermedius isolates of human and animal origins.
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FIG 1 Distribution of oxacillin MICs determined by BMD for 115 isolates of S. pseudintermedius isolates of human and animal origins.

Staphylococcus pseudintermedius Methicillin Resistance

breakpoint of ⱕ2 g/ml (Fig. 1). In contrast, 78/78 mecA-negative
isolates were susceptible to oxacillin (i.e., 0% MEs) (Table 3). Repeat testing confirmed all VMEs, and no trend in SCCmec type or
rep-PCR pattern was observed for isolates that yielded VMEs for
either oxacillin or cefoxitin (data not shown).
Many laboratories routinely test both oxacillin and cefoxitin
MICs for S. aureus isolates and report an isolate as oxacillin resistant if it is resistant to either oxacillin or cefoxitin. Therefore, we
evaluated if this combined strategy could correctly identify MRSP,
despite VMEs observed for oxacillin and cefoxitin MICs individually. Using the M100-S25 S. aureus/S. lugdunensis oxacillin and

cefoxitin MIC breakpoints, MICs indicating susceptibility to both
oxacillin and cefoxitin were observed for 7 (18.9%) of 37 mecApositive isolates.
Disk and MIC data interpreted by the CLSI M100-S25 breakpoints for CoNS yielded 11/37 mecA-positive isolates interpreted
as susceptible by cefoxitin disk (29.7% VMEs) and 0/78 mecAnegative isolates interpreted as resistant (0% MEs, Table 3 and Fig.
3). There are no cefoxitin MIC breakpoints for CoNS. The M100S25 CoNS oxacillin MIC breakpoints are the same as the CLSI
VET01-S2 S. pseudintermedius oxacillin MIC breakpoints (Table
1). Oxacillin MICs were interpreted as indicating resistance for

TABLE 3 Phenotypic susceptibility test agreement with mecA PCR results for 115 S. pseudintermedius isolates evaluated in this study
Phenotypic test and breakpoint standard

Criterion for
resistance

% CA with mecA
PCR result

No. (%) of VMEs

No. (%) of MEs

Cefoxitin DD
CLSI M100 S25 S. aureus/S. lugdunensis
CLSI M100 S25 CoNS
EUCAST S. pseudintermedius

ⱕ21 mm
ⱕ24 mm
⬍35 mm

75.7
90.4
57.4

28 (75.7)
11 (29.7)
1 (2.7)

0 (0.0)
0 (0.0)
48 (61.5)

ⱖ4 g/ml

71.3

33 (89.2)

0 (0.0)

Oxacillin MIC
CLSI M100 S25 S. aureus/S. lugdunensis
CLSI M100 S25 CoNS/CLSI VET01 S2 S.
pseudintermedius

ⱖ4 g/ml
ⱖ0.5 g/ml

93.0
99.1

8 (21.6)
0 (0)

0 (0.0)
1 (1.3)

Oxacillin DD, CLSI VET01 S2 S. pseudintermedius
PBP2a uninduced, NAa
PBP2a induced, NA

ⱕ17 mm
Positive
Positive

99.1
96.5
100

0 (0)
4 (10.8)
0 (0.0)

1 (1.3)
0 (0.0)
0 (0.0)

Cefoxitin MIC, CLSI M100 S25 S. aureus/S.
lugdunensis

a

NA, not applicable.
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FIG 3 Distribution of cefoxitin growth inhibition zone diameters for 115 S. pseudintermedius isolates of human and animal origins.
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TABLE 4 Performance of commercial automated systems when testing 115 isolates of S. pseudintermedius for oxacillin susceptibilitya
CLSI M100-S25 S. aureus/S. lugdunensis oxacillin
breakpoint (R,b ⱖ4 g/ml)

CLSI M100-S25 CoNS oxacillin breakpoint (R, ⱖ0.5
g/ml)

System/panel (concn range [g/ml])

CA (%)

No. (%) of VMEs

No. (%) of MEs

CA (%)

No. (%) of VMEs

No. (%) of MEs

BD Phoenix PMIC-8 (0.25, 0.5, 1, 2)
bioMérieux Vitek2 AST-GP71 (0.5, 1, 2)c
Beckman Coulter MicroScan Pos MIC 29
(0.25, 0.5, 1, 2)

90.4
93.0
95.7

11 (29.7)
8 (21.6)
5 (13.5)

0 (0.0)
0 (0.0)
0 (0.0)

95.7
98.3
99.1

4 (10.8)
1 (2.7)
0 (0.0)

1 (1.3)
1 (1.3)
1 (1.3)

37/37 mecA-positive isolates by these breakpoints (0% VMEs) and
susceptibility for 77/78 mecA-negative isolates (i.e., 1.3% MEs)
(Table 3 and Fig. 1). The VET01-S2 document also includes oxacillin disk breakpoints for S. pseudintermedius, whereas oxacillin
disk testing is no longer recommended for human isolates of
staphylococci. Oxacillin disk test results, interpreted by the
VET01-S2 breakpoint, indicated resistance for 37/37 mecA isolates
(0% VMEs) and susceptibility for 77/78 mecA-negative isolates
(1.3% MEs). This ME was observed for the same mecA-negative
isolate that was oxacillin resistant by MIC (Fig. 2).
EUCAST cefoxitin disk breakpoints for S. pseudintermedius
(Table 1) were evaluated. One of 37 mecA-positive isolates was
interpreted as susceptible (2.7% VMEs). This isolate had a measured cefoxitin zone of 38 mm, which was reproduced twice. In
contrast, 48/78 mecA-negative isolates were resistant to cefoxitin
by the EUCAST disk breakpoint, a 61.5% ME rate.
Performance comparison of automated susceptibility test
systems. The performance of three commercial, automated susceptibility test systems, the BD Phoenix, bioMérieux Vitek 2, and
Beckman Coulter MicroScan, was assessed. The test panels, MIC
ranges, and performance compared to mecA PCR are summarized
in Table 4. Notably, 0/37 mecA-positive isolates had a cefoxitin
MIC of ⬎4 g/ml—which represents a 100% cefoxitin VME rate
for all three antimicrobial susceptibility test systems (not shown).
Given this poor performance, only oxacillin MICs were evaluated,
and they were interpreted manually by using the CLSI M100-S25
S. aureus/S. lugdunensis and M100-S25 CoNS/VET01-S2 S. pseudintermedius oxacillin MIC breakpoints. When interpreted by the
S. aureus/S. lugdunensis oxacillin breakpoint, 11 (29.7%), 8
(21.6%), and 5 (13.5%) VMEs were obtained with the Phoenix,
Vitek 2, and MicroScan systems, respectively. No MEs were observed. When evaluated by the M100-S25 CoNS/VET01-S2 S.
pseudintermedius breakpoint, 4 (10.8%), 1 (2.7%), and 0 (0.0%)
VMEs were obtained with the Phoenix, Vitek 2, and MicroScan
systems, respectively. When these isolates were retested, the VME
obtained with the Vitek 2 system was resolved (i.e., the MIC of 0.5
g/ml was ⱕ0.25 g/ml on retesting) and all of the VMEs obtained with the Phoenix system were reproduced. Two of the
Phoenix VMEs were obtained with isolates that also had lower
MICs in the other commercial test systems. One, a canine isolate,
had an oxacillin MIC of 0.5 g/ml in the Vitek 2 system and 1
g/ml in the MicroScan system, and the other, a porcine isolate,
had oxacillin MICs of 0.5 and 1 g/ml in those systems, respectively. Notably, all four isolates had oxacillin MICs of ⬎16 g/ml
by the BMD method. One ME (1.3%) was observed when the
M100-S25 CoNS/VET01-S2 S. pseudintermedius breakpoint was
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used in all three systems, for the same canine isolate that yielded a
ME by the BMD and DD methods. One growth failure was observed, for a mecA-positive isolate, in the Vitek 2 system. This was
confirmed by repeat testing. The overall CA levels when using the
M100-S25 CoNS/VET01-S2 oxacillin S. pseudintermedius breakpoint were 95.7, 98.3, and 99.1%, for the Phoenix, Vitek 2, and
MicroScan systems, respectively.
PBP2a test. The Alere PBP2a test, when performed with colonies from the edge of the cefoxitin zone, was 100% sensitive and
100% specific, compared to the mecA PCR result. In contrast, if it
was performed uninduced, following the package insert instructions for S. aureus, four mecA-positive isolates were repeatedly
negative for PBP2a (n ⫽ 3 replicates), yielding a sensitivity of
89.2% and a specificity of 100%. No correlation was found between isolates that required induction and oxacillin MIC or cefoxitin disk zones (data not shown).
DISCUSSION

Clinical laboratories almost universally rely on the use of the surrogate agent cefoxitin to detect mecA-mediated beta-lactam resistance when testing human isolates of staphylococci (27). The cefoxitin disk test has been shown in several studies to be the most
reliable predictor of the presence of mecA in both S. aureus and
CoNS. However, the present study demonstrates that this test falls
short for SIG isolates of both human and veterinary origins. Regardless of the breakpoint employed, cefoxitin VME rates compared to mecA PCR were unacceptably high and ranged from 3 to
89% (Table 3). On the low end of this range was the EUCAST
cefoxitin disk test, with 3% VMEs observed among the 37 mecApositive isolates tested. However, we obtained a very high ME rate
(62.8%) when using this breakpoint, further demonstrating the
limitation of this surrogate agent for SIG. Indeed, we were unable
to find a clear breakpoint in cefoxitin zones that could differentiate mecA-positive from mecA-negative isolates (Fig. 3). No correlation between SCCmec type and/or rep-PCR clonal type and performance of cefoxitin tests was identified, suggesting that our
findings were not related to a specific lineage of this organism
group. It should be noted that we incubated all tests for 24 h,
which is longer than the recommended 16- to 20-h incubation
endorsed by EUCAST (26)—we cannot exclude the possibility
that the additional 4 h of incubation contributed to some MEs.
Nonetheless, it is clear that neither the cefoxitin nor the oxacillin
test will adequately detect mecA-mediated resistance in all species
of Staphylococcus— both VMEs and MEs (32) have been documented. In particular, the cefoxitin disk test performs poorly with
S. saprophyticus (32) and S. simulans (33) when results are inter-
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a
Oxacillin MICs were interpreted by using the CLSI M100-S25 S. aureus/S. lugdunensis or CoNS breakpoints; the reference is a mecA PCR result. Results obtained with all three
systems are currently for research use only.
b
R, resistance.
c
One isolate had growth failure (repeated twice) in the AST-GP71 panel.
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oxacillin MICs interpreted by M100-S25 CoNS breakpoints from
all three instruments demonstrated a ⬎95% CA. These systems
appear to be able to detect mecA-mediated resistance if the CoNS
breakpoints are used, with the exception of the BD Phoenix system, where a 10.8% VME rate was noted. Importantly, 0 of the 37
mecA-positive isolates had a positive cefoxitin screening result in
these systems, reinforcing the poor performance of this surrogate
agent for SIG and the potential negative implication of misidentification of SIG as S. aureus. Furthermore, it is worth noting that
we encountered some difficulty extracting oxacillin results from
the commercial platforms. For example, the Phoenix system required the operator to annotate “unspecified” for an organism’s
identification in order to retrieve oxacillin MIC results, and Vitek
2 required similar manipulation of the platform’s software and/or
setting to obtain results. Laboratories should be aware that while
the results of the present study are encouraging, they are reported
for research use only and would require laboratory verification
prior to use in determining patient care. Therefore, the oxacillin
disk test is an attractive option.
The Alere PBP2a Culture Colony test demonstrated 100%
agreement with the mecA PCR results, if colonies from the edge of
the cefoxitin zone were used for testing. Cefoxitin, rather than
oxacillin, was used as the inducer for mecA expression in our study
on the basis of literature about S. aureus that demonstrates that
cefoxitin is the superior inducer of mecA expression in this species
(35). It is perhaps fortuitous that we chose this approach, since it
allows laboratories that do not stock an oxacillin disk to perform a
PBP2a test for S. pseudintermedius with colonies from the edge of
the cefoxitin disk (which is stocked by nearly all laboratories in the
United States) zone of inhibition.
Throughout this study, we encountered one isolate, of canine
origin, that yielded a consistently elevated oxacillin MIC and small
oxacillin zones but was mecA and mecC negative by PCR. This
isolate had an oxacillin zone diameter of 12 mm, a cefoxitin zone
diameter of 27 mm, and an oxacillin MIC of ⬎16 g/ml but a
cefoxitin MIC of ⱕ4 g/ml. The oxacillin MICs were similarly
high (1 to ⬎2 g/ml) by all three commercial systems. The mechanism of oxacillin resistance in this isolate remains to be determined, but it may be due to either hyperexpression of blaZ or
other altered penicillin-binding proteins not detected by our molecular analysis-based methods. While these alternative mechanisms of low-level oxacillin resistance have been documented in S.
aureus, they have not, to our knowledge, been confirmed in isolates of SIG.
In summary, our data demonstrate that the VET01-S2 oxacillin disk and MIC breakpoints are appropriate for use with S.
pseudintermedius isolates obtained from human clinical specimens. Laboratories should attempt to identify coagulase-positive
staphylococci that appear atypical in morphology (double zone of
hemolysis, white in color) by MALDI-TOF MS or nucleic acid
methods to ensure the appropriate determination and interpretation of oxacillin MICs and DD zones.
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preted by using the CLSI CoNS breakpoints. The mechanisms
behind these discrepancies are unclear, but the mechanism of beta-lactam resistance in the staphylococci is complex, involving the
participation of both acquired and native PBP-encoding genes;
therefore, differences in phenotypic resistance among the various
staphylococcal species are not unanticipated (34).
Oxacillin MIC and disk testing, when interpreted by the
VET01-S2 S. pseudintermedius breakpoints, was most accurate at
identifying mecA among the SIG isolates evaluated. All 37 mecApositive isolates were correctly interpreted as oxacillin resistant,
and 77/78 mecA/mecC-negative isolates were interpreted as oxacillin susceptible. Similar to our findings, Bemis and colleagues
found 29.1% VMEs and 0% MEs for the cefoxitin disk test among
a collection of 380 veterinary isolates of S. pseudintermedius (88
mecA positive) (22). This laboratory also tested S. pseudintermedius with the oxacillin disk test interpreted by the CLSI historical
CoNS oxacillin breakpoint that was last published in 2008 in CLSI
M100-S18 (and is the same as the current CLSI VET01-S2 S.
pseudintermedius disk breakpoint). Among 666 isolates (230 mecA
positive), they found 0.9% VMEs and 0.6% MEs. Similarly, when
Schissler and colleagues evaluated a collection of 30 mecA-positive
veterinary isolates of S. pseudintermedius, only 6.7 or 43.3% were
resistant when the cefoxitin disk test was used and interpreted
according to the CLSI M100-S25 S. aureus/S. lugdunensis or CoNS
breakpoint, respectively. These findings, which correlated with
our study of human isolates, confirm that cefoxitin is not predictive of mecA-mediated resistance in S. pseudintermedius isolates,
regardless of the isolate source. In response to the data presented
here, the CLSI Antimicrobial Susceptibility Testing Subcommittee voted in June 2015 to add S. pseudintermedius-specific oxacillin
MIC and disk breakpoints to the forthcoming M100-S26 document. These new breakpoints for human isolates of S. pseudintermedius are the same as those published in the VET01-S2 document and will help raise awareness regarding the use of oxacillin
tests to detect mecA-mediated resistance in S. pseudintermedius
among clinical laboratories, in particular as cefoxitin testing has
been recommended and oxacillin testing has been discouraged by
the CLSI for other species of staphylococci. However, the use of
these new oxacillin breakpoints, when they are published, is contingent on the laboratory’s accurate identification of S. pseudintermedius when it is isolated from diagnostic specimens. Accurate
identification may be a challenge to laboratories that do not have
MALDI-TOF MS technology for bacterial identification and impossible for laboratories that rely solely on a coagulase or S. aureus
latex test for the identification of staphylococci, as both tests yield
positive reactions with SIG isolates. We have found that commercial systems will identify isolates of S. pseudintermedius as S. intermedius (L. Westblade, unpublished data). Thus, if these isolates
are encountered, laboratories should perform oxacillin MIC or
disk tests on them to predict the presence of mecA.
Nonetheless, the inclusion of oxacillin disk breakpoints in
M100-S26 is particularly helpful to laboratories in the United
States, as no commercial antimicrobial susceptibility test systems
are cleared by the FDA for S. pseudintermedius. While S. pseudintermedius is the only Staphylococcus species for which the oxacillin
disk test would be used, many laboratories use oxacillin DD as a
surrogate test for penicillin susceptibility in isolates of Streptococcus pneumoniae. These laboratories would thus already have the
disk on hand and quality controlled. As an alternative, the commercial antimicrobial susceptibility test systems performed well;
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and bioMérieux for providing antimicrobial susceptibility test panels for
this study.
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